Literature DB >> 25172100

Report of clinical studies on chronochemotherapy for advanced non-small cell lung cancer in China.

Mei Ji1, Xiao-Dong Li, Hanze Zhang, Zhong-Hua Ning, Xiaofei Zhang, Wei-Qing Zhao, Li-Na Zhu, Jie Li, Chang-Ping Wu.   

Abstract

Chronochemotherapy has been proposed as a promising modality to provide timely optimized medication to achieve maximum efficacy with minimum side effect for patients with non-small cell lung cancer for years. We collected the data of 11 clinical studies performed in China with the purpose to compare the difference between chronochemotherapy and traditional chemotherapy. Results showed that chronochemotherapy has a more favorable efficacy and safety than traditional chemotherapy.

Entities:  

Mesh：

Year:  2014        PMID： 25172100     DOI： 10.1007/s13277-014-2539-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  19 in total

Review 1.  Role of circadian clocks in the development and therapeutics of cancer.

Authors:  X-L Huang; C-J Fu; R-F Bu
Journal:  J Int Med Res       Date:  2011       Impact factor: 1.671

2.  American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Authors:  Christopher G Azzoli; Giuseppe Giaccone; Sarah Temin
Journal:  J Oncol Pract       Date:  2010-01       Impact factor: 3.840

Review 3.  Chronomodulated chemotherapy for colorectal cancer: failing the test of time?

Authors:  Chris H Takimoto
Journal:  Eur J Cancer       Date:  2006-01-24       Impact factor: 9.162

Review 4.  Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  G D'Addario; E Felip
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

Review 5.  Chronotherapeutics: the relevance of timing in cancer therapy.

Authors:  Francis Lévi
Journal:  Cancer Causes Control       Date:  2006-05       Impact factor: 2.506

Review 6.  Circadian-system alterations during cancer processes: a review.

Authors:  M C Mormont; F Lévi
Journal:  Int J Cancer       Date:  1997-01-17       Impact factor: 7.396

7.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

Authors:  Federico Cappuzzo; Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenas; Aleksandra Szczésna; Erzsébet Juhász; Emilio Esteban; Olivier Molinier; Wolfram Brugger; Ivan Melezínek; Gaëlle Klingelschmitt; Barbara Klughammer; Giuseppe Giaccone
Journal:  Lancet Oncol       Date:  2010-05-20       Impact factor: 41.316

Review 8.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Authors:  Julian R Molina; Ping Yang; Stephen D Cassivi; Steven E Schild; Alex A Adjei
Journal:  Mayo Clin Proc       Date:  2008-05       Impact factor: 7.616

Review 9.  Circadian timing in cancer treatments.

Authors:  Francis Lévi; Alper Okyar; Sandrine Dulong; Pasquale F Innominato; Jean Clairambault
Journal:  Annu Rev Pharmacol Toxicol       Date:  2010       Impact factor: 13.820

10.  Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.

Authors:  F A Lévi; R Zidani; J M Vannetzel; B Perpoint; C Focan; R Faggiuolo; P Chollet; C Garufi; M Itzhaki; L Dogliotti
Journal:  J Natl Cancer Inst       Date:  1994-11-02       Impact factor: 13.506
View more
  1 in total

1.  Chronotherapy in practice: the perspective of the community pharmacist.

Authors:  Gagandeep Kaur; Yuh-Lin Gan; Craig L Phillips; Keith Wong; Bandana Saini
Journal:  Int J Clin Pharm       Date:  2015-12-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.